AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 252 min read$JNJ

Johnson & Johnson Clinical Trials Show Progress Across Key Therapies

Johnson & Johnson reported positive results from clinical trials for Tremfya and Carvykti. Tremfya met primary and secondary endpoints in a psoriatic arthritis study, showing improvement in disease activity scores. Carvykti demonstrated 50% five-year progression-free survival in multiple myeloma patients. JNJ shares were down 0.20% to $270.24 at the time of publication.

Original reporting
benzinga.com
Published Sep 25, 2026, 3:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 3:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$JNJ
Bullish
high confidence
Mentioned
$JNJ
Relevance
7/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$JNJBullishMed
01

Why it matters

The data suggest continued efficacy and safety, which could translate into incremental sales growth.

02

Market read

Positive trial results may lift JNJ and related biotech stocks.

03

What to watch

Potential competition from emerging IL‑23 inhibitors and next‑generation CAR‑T products could temper upside.

Relevance 7/10Novelty 8/10Timing: today

Background

Johnson & Johnson reported new clinical data for two of its key biologic products.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Johnson & Johnson disclosed positive Phase 4 results for Tremfya in psoriatic arthritis and five‑year progression‑free survival data for Carvykti in multiple myeloma.

Expected impact

modest upside potential, likely 1‑3% rally if market digests data

Evidence & confidence

Both therapies are already approved; new efficacy data can drive demand and reinforce revenue outlook.

Market effects

Sector

Strengthens outlook for biotech/pharma sector, especially IL‑23 inhibitors and CAR‑T therapies.

Regional

U.S. healthcare stocks may see modest lift.

Global

Reinforces confidence in late‑stage oncology and immunology pipelines worldwide.

Counterpoint

What could challenge this read

Investors may question the commercial impact given modest price movement and limited patient pool.

Key entities

  • company
    Johnson & Johnson

    Pharmaceutical and medical devices conglomerate.

  • drug
    Tremfya

    IL‑23 inhibitor for psoriatic arthritis.

  • drug
    Carvykti

    CAR‑T cell therapy for multiple myeloma.

Read at source← All news

Related articles

SEP 25
$JNJHigh

The 1 Number That Decides Whether a Dividend Lasts Your Whole Retirement

Johnson & Johnson (JNJ) extended its 64-year dividend growth streak with a 3.1% quarterly raise, supported by projected $21 billion in free cash flow. The company's oncology drugs, like CARVYKTI and TREMFYA, offset losses from Stelara biosimilars. JNJ's dividend yield is 1.94%, and shares are up 31.11% year-to-date. The company aims for a 65th consecutive hike in 2027, subject to free cash flow and litigation risks.

aol.com2 min
SEP 25
$JNJHighAI 8/10

Johnson & Johnson Reports TREMFYA STAR Trial Results

Johnson & Johnson (JNJ) reported positive Phase 4 STAR trial results for TREMFYA in treating axial psoriatic arthritis. The drug met primary and major secondary endpoints, showing improvements in disease activity, axial symptoms, and MRI-measured inflammation at Week 24. The safety profile was consistent with previous findings. Detailed results will be presented at a future scientific congress.

grafa.com2 min
SEP 25
$JNJLow

Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

Johnson & Johnson (JNJ) reported that 50% of patients in a Phase 2 study of CARVYKTI® (ciltacabtagene autoleucel) for early-line relapsed/refractory multiple myeloma achieved five-year treatment-free remission. The study, presented at the International Myeloma Society Annual Meeting, showed a 69.2% five-year overall survival rate and 60.5-month median progression-free survival. The company suggests earlier treatment may increase long-term remission and disease control.

prnewswire.com2 min
SEP 25
$JNJMedAI 8/10

Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study

Johnson & Johnson (JNJ) reported positive results from the Phase 4 STAR study of TREMFYA (guselkumab) in patients with axial psoriatic arthritis (PsA). The drug met primary and major secondary endpoints, showing improvement in spinal pain, stiffness, and MRI-confirmed inflammation. JNJ aims to position TREMFYA as a first-line treatment for axial PsA, an area with significant unmet needs. Detailed results will be presented at an upcoming scientific congress.

prnewswire.com2 min
SEP 25
$JNJMedAI 8/10

Half of patients in a J&J study were alive without worsening myeloma five years after one infusion

Johnson & Johnson (JNJ) reported that 50% of patients in a Phase 2 study of CARVYKTI® for multiple myeloma were alive and progression-free five years after a single infusion. The study, presented at the International Myeloma Society Annual Meeting, showed a 69.2% overall survival rate and 60.5-month median progression-free survival. CARVYKTI is approved in 17 markets and has treated over 13,000 patients globally, according to the company.

stocktitan.net2 min